Published in Leukemia on June 12, 2008
Characterization of chronic myeloid leukemia stem cells. Am J Hematol (2011) 1.15
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood (2009) 1.11
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica (2009) 1.00
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program (2013) 0.91
New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int (2012) 0.88
Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation. PLoS One (2014) 0.86
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother (2011) 0.85
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell (2015) 0.81
A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice. Biomed Res Int (2013) 0.81
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy. Cancer Cell Int (2013) 0.79
New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia. Blood Cells Mol Dis (2009) 0.77
Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy. Oncoimmunology (2013) 0.77
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia (2016) 0.75
SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway. Biomed Res Int (2014) 0.75
Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia. Contemp Oncol (Pozn) (2012) 0.75
Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplant (2014) 0.75
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Front Immunol (2017) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med (2003) 6.68
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A (2004) 2.58
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A (2003) 2.32
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood (2007) 2.29
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood (2006) 2.14
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 1.94
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
Graft-versus-leukemia reactions in allogeneic chimeras. Blood (2003) 1.84
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63
Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics (2000) 1.51
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res (2005) 1.43
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood (2002) 1.39
Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 1.11
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06
Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol (2006) 0.97
Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood (2003) 0.95
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol (2007) 0.92
T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A (1998) 0.92
Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol (2003) 0.91
CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol (1999) 0.84
CD7 expression by CD34+ cells in CML patients, of prognostic significance? Eur J Haematol (2003) 0.80
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Evolutionary families of peptidases. Biochem J (1993) 5.81
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
A simple, easy, and inexpensive method for monitoring ETCO2 through nasal cannulae. Anesthesiology (1987) 4.19
Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09
Families of serine peptidases. Methods Enzymol (1994) 2.94
A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65
Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60
MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48
An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44
Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Pectic polysaccharides of growing plant tissues. Biochem J (1967) 2.24
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J (1980) 2.20
Neutral proteinases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J (1976) 2.17
Human liver cathepsin L. Biochem J (1985) 2.16
Lysosomal acid proteinase of rabbit liver. Biochem J (1967) 2.12
The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J (1974) 2.11
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2001) 2.11
The inhibition of tissue acid proteinases by pepstatin. Biochem J (1972) 2.06
Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 2.03
Heredopathia atactica polyneuritiformis: Refsum's disease. Acta Neurol Scand (1985) 2.03
CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Families of cysteine peptidases. Methods Enzymol (1994) 1.98
Births of normal daughters after MicroSort sperm separation and intrauterine insemination, in-vitro fertilization, or intracytoplasmic sperm injection. Hum Reprod (1998) 1.97
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood (1997) 1.96
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 1.94
Hypertension and convulsions in children receiving cyclosporin A. Lancet (1982) 1.89
Human cathepsin H. Biochem J (1980) 1.88
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia (1994) 1.88
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia (1994) 1.88
An improved color reagent for use in Barrett's assay of Cathepsin B. Anal Biochem (1976) 1.87
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood (1998) 1.87
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia (2003) 1.84
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood (2000) 1.84
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia (1995) 1.81
Action of rat liver cathepsin L on collagen and other substrates. Biochem J (1982) 1.73
Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J (1986) 1.71
Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem J (1984) 1.69
MEROPS: the peptidase database. Nucleic Acids Res (2000) 1.69
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia (2010) 1.67
Prolymphocytic leukaemia. Br J Haematol (1974) 1.66
Human cathepsin G. Catalytic and immunological properties. Biochem J (1976) 1.65
The many forms and functions of cellular proteinases. Fed Proc (1980) 1.64
Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet (1983) 1.64
Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem (1997) 1.63
Chicken alpha2-proteinase inhibitor: a serum protein homologous with ovoinhibitor of egg white. Biochim Biophys Acta (1974) 1.63
Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol Chem Hoppe Seyler (1988) 1.63
The degradation of cartilage proteoglycans by tissue proteinases. Proteoglycan structure and its susceptibility to proteolysis. Biochem J (1977) 1.63
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63
Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem (1987) 1.61
Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR) Br J Haematol (1994) 1.60
Bone-marrow transplantation for leukaemia. Lancet (1995) 1.60
Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (1987) 1.59
Human lysosomal elastase. Catalytic and immunological properties. Biochem J (1976) 1.59
The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta (1977) 1.59
Lysosomes. Essays Biochem (1976) 1.58
The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun (1984) 1.56
Alpha 2-macroglobulin. Methods Enzymol (1981) 1.55
Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol (1978) 1.55
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem (1999) 1.52
Degradation of fructose-1,6-bisphosphate aldolase by cathepsin B. Biochem J (1980) 1.52
Lysis and killing of bacteria by lysosomal proteinases. Infect Immun (1976) 1.50
Calpain inhibition by peptide epoxides. Biochem J (1985) 1.49
1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk Res (1983) 1.48
Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol (1997) 1.48
Elastinolytic activity of human cathepsin L. Biochem J (1986) 1.48
The possible role of neutrophil proteinases in damage to articular cartilage. Agents Actions (1978) 1.48
Co-trimoxazole for prevention of infection in acute leukaemia. Lancet (1978) 1.47